Steven Messe, TCT 2022: Sentinel® cerebral protection system efficacy in reducing all stroke/disabling stroke, the PROTECTED-TAVR trial (a neurologist’s perspective)
The PROTECTED-TAVR trial studied the efficacy of using an embolic protection device (Sentinel® cerebral protection system) during transcatheter aortic valve replacement in reducing the incidence of stroke/disabling stroke. In this touchCARDIO interview, we speak with Dr Steven Messe (University of Pennsylvania, Philadelphia, PA, USA) to give a Neurologist’s perspective on the findings of the PROTECTED-TAVR study.
The presentation entitled ‘Clinical Implications of PROTECTED TAVR: A Neurologist’s Perspective’ was delivered at the Transcatheter Cardiovascular Therapeutics (TCT) conference, 16 – 19, September 2022.
Questions:
- What is the definition of disabling stroke? (0:13)
- Could you give us a brief overview of the PROTECTED-TAVR study? (2:03)
- What were the findings of the PROTECTED-TAVR study in terms of incidence of all stroke and disabling stroke? (3:25)
- Why was the stroke rate lower than expected? (5:07)
- What were the conclusions in terms of future use of the Sentinel® cerebral protection system? (6:36)
Disclosures: Steven Messe is a consultant for Boston Scientific Corporation and EmStop.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of TCT 2022
